Table 2.
Cervical HIV RNA Shedding by Time Since ART Initiation
| Time Since ART Initiation | ||||
|---|---|---|---|---|
| <6 months | 6–12 months | >12 months | P valuea | |
| Detectable plasma VL (377 visits, 309 women) | ||||
| Shedding, % (n/N visits) | 20.6 (40/194) | 27.4 (17/62) | 26.5 (32/121) | .195 |
| Log10 genital VL among shedders, mean (95% CI)a | 3.42 (3.13–3.70) | 3.75 (3.36–4.13) | 3.82 (3.44–4.19) | .040 |
| Undetectable plasma VL (1433 visits, 900 women) | ||||
| Shedding, % (n/N visits) | 8.3 (33/398) | 5.1 (23/449) | 4.6 (27/586) | .032 |
| Log10 genital VL among shedders, mean (95% CI)a | 3.17 (2.97–3.37) | 3.16 (2.92–3.34) | 3.10 (2.86–3.33) | .536 |
Missing data: for 36 visits with a genital VL assessment, there was no plasma VL measurement within 30 days.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; n, number of visits with shedding; N, total number of visits; VL, viral load.
a To account for repeated measures within intervals, P values were derived from generalized linear mixed models with a binary distribution for the outcome of shedding versus no shedding and P values and estimated mean log genital VLs were derived from linear mixed models. Models were adjusted for a combined variable of study (Partners in Prevention [PiP], Couples Observation Study, and Partners PrEP Study) and randomization to acyclovir in PiP.